Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. - Wikidata - awgldk - TriplyDB

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

http://www.wikidata.org/entity/Q34601527

about

Advances in rheumatology: new targeted therapeutics Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Adverse effects of biologics: a network meta-analysis and Cochrane overview Golimumab for rheumatoid arthritis Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Biologic interventions for fatigue in rheumatoid arthritis Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis Advances in the treatment of polyarticular juvenile idiopathic arthritis Advances in the treatment of rheumatoid arthritis.Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy Combination therapy with biologic agents in rheumatic diseases: current and future prospects Golimumab for the treatment of ulcerative colitis A multi-targeted approach to suppress tumor-promoting inflammation Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis TNF inhibitor therapy for rheumatoid arthritis Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis Incorporating data from various trial designs into a mixed treatment comparison model.[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data].Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence.Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison.Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.Golimumab.Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

P2860

Q21093257-BCE6062B-1463-42C4-9F37-8EE03B792E41 Q21134808-0A235004-BC26-4461-B3DA-911189D34A53 Q24185797-CB1D6F87-DACD-4895-9522-BC63A90D3EA8 Q24234197-7A5E21B0-807B-4C1D-B33D-619D7FD82657 Q24240895-35CF5F21-033D-4B2A-ADCD-53EB731E5687 Q24631295-CDBC08CE-3654-4FBD-AE0C-E6B0996530F7 Q26471538-4A08ABA4-816A-47E8-BB17-F6AAC5394322 Q26739150-9F2E46CB-CF2D-426E-9C6E-8D294486A980 Q26824970-2685E781-FBE1-4B73-B995-F3790F0202C5 Q26849243-820F3F48-DE9C-4C73-B285-FB04860A681F Q26852235-DBEB8FF6-FE85-4758-A267-7479EB46DF32 Q27001017-E23EF6DB-5F02-4FC0-971A-6CCA365F214B Q27691822-E2661434-3EC7-4CD0-9716-FE3CD727EC9F Q27694496-9AE4AEC2-77CB-4202-8F39-1ADA39BA6F67 Q28066250-21298963-B0D7-4C3F-BD08-8728D359C783 Q28236322-D4CE8AC5-5343-4278-9DAB-2921AAAC83EB Q28393278-A2FF5FC7-0571-4349-BDE1-948D81199164 Q28547851-EAD59EAD-E985-4D72-A206-AE4095ED41F8 Q28674280-0A813EA8-C6E8-40F7-85E5-449535D8486D Q28972424-133503D5-3F8C-4AFA-91FC-351D918E6670 Q30235341-82284CC8-052D-40ED-8DFA-9581DF782A47 Q30240183-A18C3BA3-6679-4CAA-BB99-2143981A3CF4 Q30240212-4F428311-0B8E-4F39-8242-18C593A1D5B6 Q30576366-32A465E3-1B09-4F70-8D84-8EFE5995FE02 Q30594247-52F8E3D2-6134-4C58-86F5-BF71C20E9902 Q30699616-56F161B2-5A62-401C-B8FD-6DE75EDC3506 Q30717002-8C66EBCA-B50B-413F-B5FD-B624826D7B06 Q30872562-0DA0ADF2-ABCC-4A90-9F42-754AD8216A7A Q31039549-C6709FF2-5A85-41D4-A3D5-1F81397C701F Q33667897-C30D14FA-F561-4EE7-B5BD-5A16CFE83C5F Q33690668-78683FD3-99EF-4ED7-9964-53EFB94108B2 Q33754764-B63E86FD-5BB2-4D1F-B960-592DD2322BEE Q33833623-32012AC6-7429-4F39-9206-2FE07C8B6A8C Q33956485-7DAD4A3D-5154-4591-B96F-6D9DBE11805F Q33968506-AAD70481-6C03-48A8-B119-807331F37560 Q33973884-B5FF8D59-BCCE-46C9-8122-251F66EBA7EC Q34092224-18371842-02A7-4D66-8986-605E064E8CDB Q34456715-4EB3FFF7-94AE-4517-9632-7DDAA8E2EABF Q34500921-8AFE2D23-EE61-4941-AEBB-5F7B459CBC0F Q34523450-A9F61287-E86D-4BE6-AFB6-78730C661CF5

P2860

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

http://www.wikidata.org/entity/Q34601527

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@ast

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@en

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@nl

type

label

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@ast

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@en

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@nl

prefLabel

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@ast

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@en

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@nl

P1433

Q34601527-8663F649-0AB6-4961-A1D2-CD4B9F3F2032

P1476

Q34601527-3A134189-9727-4502-89A0-FC6C87B40344

P2093

Q34601527-0383FD12-6ED9-43D6-9B62-51F19C7F1BBB

Q34601527-067E00E9-11F1-443D-A667-9A9FD239B007

Q34601527-1C3429F0-2629-4E1C-AE3E-69FA605FA926

Q34601527-528E2272-7456-4C71-AAA9-97B48A6418F8

Q34601527-7D87458E-5282-4E32-AF75-C45B966E9BFB

Q34601527-7DEAD7BE-0645-4BBD-9A9F-573C8DF83E7B

Q34601527-81187871-AC0A-48DF-8A36-D73ABBF78646

Q34601527-8A1BCCCB-4784-406D-848E-DF55F74FCA4E

Q34601527-BD174C84-FD5D-41B2-8877-DC9064F88AE6

Q34601527-C50F8594-0B98-4002-B761-E33DBD77EF1E

P2860

Q34601527-0F02FADE-AE66-45ED-A0A7-9DAC9B92B613

Q34601527-0F6CEDF3-07BB-4F5A-8758-89FB4A613980

Q34601527-1302BB30-5857-4D80-95A3-F0887D29F9BC

Q34601527-20A6026D-163D-475E-9B0E-8DFE0CFC1B7D

Q34601527-296AD3F2-CD22-4A24-B5D7-B0C3D912B133

Q34601527-4490E16D-AD20-485D-8F84-19E76BA609CF

Q34601527-5447F861-ADC7-45B6-8EAC-1F0172F93218

Q34601527-7E3D7733-1043-4B1F-A993-D51703297FFB

Q34601527-84D10020-1044-47DF-BD17-7F8FAA747BCC

Q34601527-91DA6C3A-6B13-47D9-81CD-B70AE5E67AF6

P304

Q34601527-34209A72-86B6-4E3E-A3CA-07F5EDEEDE92

P31

Q34601527-8C0DF449-1B8E-4D97-BD34-E4D2AC10042A

P356

Q34601527-B93CAE8D-A37C-4EF1-BC20-D3258FFC18C3

P407

Q34601527-31427C40-D9B6-43E0-9266-09C763AC8B21

P433

Q34601527-BDCC2D78-3146-4B52-BB1E-F4CDF009E1EA

P478

Q34601527-D529E6C1-6D08-498E-9DC2-F601BFE4E29B

P50

Q34601527-3383EE9C-3051-42AC-99B6-4B800E9C5ACF

P577

Q34601527-098565A2-9298-4382-BCA8-975E2A9AF274

P5875

Q34601527-01C3AA55-22AB-4BFF-92AD-8F41F24268DB

P698

Q34601527-5C643CC8-95BF-45B1-832C-67870FE450AA

P921

Q34601527-7B2BA251-B65A-4D88-A0D7-F9C22A42A08F

Q34601527-90061f52-e70b-4eff-bcf8-52ab236e25f0

P932

Q34601527-F3DF7C8D-8786-48EF-80C8-7DC943A26E05

P356

ARD.2008.099010

P1433

Annals of the Rheumatic Diseases

P1476

Golimumab, a human antibody to ...... therapy: the GO-FORWARD Study.

@en

P2093

E C Hsia

http://www.w3.org/2001/XMLSchema#string

E C Keystone

http://www.w3.org/2001/XMLSchema#string

GO-FORWARD Study

http://www.w3.org/2001/XMLSchema#string

J Pazdur

http://www.w3.org/2001/XMLSchema#string

J Zrubek

http://www.w3.org/2001/XMLSchema#string

M C Genovese

http://www.w3.org/2001/XMLSchema#string

M U Rahman

http://www.w3.org/2001/XMLSchema#string

M Wiekowski

http://www.w3.org/2001/XMLSchema#string

P C Miranda

http://www.w3.org/2001/XMLSchema#string

S T Hall

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

P304

789-796

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2008.099010

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23641544

http://www.w3.org/2001/XMLSchema#string

P698

19066176

http://www.w3.org/2001/XMLSchema#string

P921

P932

2674549

http://www.w3.org/2001/XMLSchema#string